Your browser doesn't support javascript.
loading
Entecavir-induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide.
Lim, I Vern; Yurttas, Nurgül Özgür; Ayer, Mesut; Poturoglu, Sule; Kinaci, Erdem; Özden, Ilgin.
Affiliation
  • Lim IV; Department of General Surgery, Liver Transplantation & Hepatopancreatobiliary Surgery Unit Basaksehir Çam & Sakura City Hospital Istanbul Turkey.
  • Yurttas NÖ; Department of Internal Medicine, Division of Hematology Basaksehir Çam & Sakura City Hospital Istanbul Turkey.
  • Ayer M; Department of Internal Medicine, Division of Hematology Basaksehir Çam & Sakura City Hospital Istanbul Turkey.
  • Poturoglu S; Department of Internal Medicine, Division of Gastroenterology Basaksehir Çam & Sakura City Hospital Istanbul Turkey.
  • Kinaci E; Department of General Surgery, Liver Transplantation & Hepatopancreatobiliary Surgery Unit Basaksehir Çam & Sakura City Hospital Istanbul Turkey.
  • Özden I; Department of General Surgery, Liver Transplantation & Hepatopancreatobiliary Surgery Unit Basaksehir Çam & Sakura City Hospital Istanbul Turkey.
Clin Case Rep ; 11(8): e7741, 2023 Aug.
Article in En | MEDLINE | ID: mdl-37575459
ABSTRACT
At 22 weeks post-transplantation for HBV-related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID-19 (ANC 0.4 × 109/L). Covid resolution and all "conventional" modifications were ineffective. Success within 2 weeks was achieved by switching entecavir to tenofovir alafenamide. A step-by-step judicious approach to post-transplant neutropenia is vital.
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Year: 2023 Type: Article